Barbara K Finck - Net Worth and Insider Trading

Barbara K Finck Net Worth

The estimated net worth of Barbara K Finck is at least $30,507 dollars as of 2024-11-13. Barbara K Finck is the Chief Medical Officer of Coherus BioSciences Inc and owns about 37,043 shares of Coherus BioSciences Inc (CHRS) stock worth over $30,505. Barbara K Finck is also the Director of Comera Life Sciences Holdings Inc and owns about 23,033 shares of Comera Life Sciences Holdings Inc (CMRA) stock worth over $2. Details can be seen in Barbara K Finck's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Barbara K Finck has not made any transactions after 2023-01-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Barbara K Finck

To

Barbara K Finck Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Barbara K Finck owns 3 companies in total, including Coherus BioSciences Inc (CHRS) , Forte Biosciences Inc (FBRX) , and Comera Life Sciences Holdings Inc (CMRA) .

Click here to see the complete history of Barbara K Finck’s form 4 insider trades.

Insider Ownership Summary of Barbara K Finck

Ticker Comapny Transaction Date Type of Owner
CHRS Coherus BioSciences Inc 2018-09-10 Chief Medical Officer
FBRX Forte Biosciences Inc 2022-03-16 director
CMRA Comera Life Sciences Holdings Inc 2023-01-04 director

Barbara K Finck Latest Holdings Summary

Barbara K Finck currently owns a total of 2 stocks. Among these stocks, Barbara K Finck owns 37,043 shares of Coherus BioSciences Inc (CHRS) as of September 10, 2018, with a value of $30,505 and a weighting of 99.99%. Barbara K Finck also owns 23,033 shares of Comera Life Sciences Holdings Inc (CMRA) as of January 4, 2023, with a value of $2 and a weighting of 0.01%.

Latest Holdings of Barbara K Finck

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CHRS Coherus BioSciences Inc 2018-09-10 37,043 0.82 30,505
CMRA Comera Life Sciences Holdings Inc 2023-01-04 23,033 0.00 2

Holding Weightings of Barbara K Finck


Barbara K Finck Form 4 Trading Tracker

According to the SEC Form 4 filings, Barbara K Finck has made a total of 0 transactions in Coherus BioSciences Inc (CHRS) over the past 5 years. The most-recent trade in Coherus BioSciences Inc is the sale of 1,760 shares on September 10, 2018, which brought Barbara K Finck around $32,701.

According to the SEC Form 4 filings, Barbara K Finck has made a total of 1 transactions in Comera Life Sciences Holdings Inc (CMRA) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Comera Life Sciences Holdings Inc is the acquisition of 6,756 shares on January 4, 2023, which cost Barbara K Finck around $8,310.

Insider Trading History of Barbara K Finck

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Barbara K Finck Trading Performance

GuruFocus tracks the stock performance after each of Barbara K Finck's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Barbara K Finck is -31.78%. GuruFocus also compares Barbara K Finck's trading performance to market benchmark return within the same time period. The performance of stocks bought by Barbara K Finck within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Barbara K Finck's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Barbara K Finck

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 2.33 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -5.03 LIMIT LIMIT LIMIT LIMIT LIMIT

Barbara K Finck Ownership Network

Ownership Network List of Barbara K Finck

No Data

Ownership Network Relation of Barbara K Finck

Insider Network Chart

Barbara K Finck Owned Company Details

What does Coherus BioSciences Inc do?

Who are the key executives at Coherus BioSciences Inc?

Barbara K Finck is the Chief Medical Officer of Coherus BioSciences Inc. Other key executives at Coherus BioSciences Inc include director & President and CEO Dennis M Lanfear , Chief Financial Officer Mcdavid Stilwell , and See Remarks Bryan J Mcmichael .

Coherus BioSciences Inc (CHRS) Insider Trades Summary

Over the past 18 months, Barbara K Finck made no insider transaction in Coherus BioSciences Inc (CHRS). Other recent insider transactions involving Coherus BioSciences Inc (CHRS) include a net sale of 223,100 shares made by Dennis M Lanfear ,

In summary, during the past 3 months, insiders sold 0 shares of Coherus BioSciences Inc (CHRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 223,100 shares of Coherus BioSciences Inc (CHRS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 223,100 shares.

Coherus BioSciences Inc (CHRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Coherus BioSciences Inc Insider Transactions

No Available Data

Barbara K Finck Mailing Address

Above is the net worth, insider trading, and ownership report for Barbara K Finck. You might contact Barbara K Finck via mailing address: C/o Protine Design Lab, 3858 Jackson St, San Francisco Ca 94118.